Stockpolly
Search
KRRO · NASDAQ · Biotechnology

Korro Bio (KRRO)

Develops RNA-editing therapeutics around OPERA and GalNAc-delivered liver programs.

$12.25
Pre-market+0.32 (+2.68%)
At close$11.93(−2.53%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000002311100
Cost of revenue000000000100
Gross profit000002311100
192721242325282920172020
Research & development141514171617202114111314
51411101088107677
Selling & marketing044440030000
General & administrative5107668877677
Other expenses0−3−3−3−300−30−100
Operating income−19−27−21−24−23−23−25−27−19−16−20−20
112222211−3411
Interest income000000000000
Other non-operating income00000000−1000
Income before tax−18−25−20−22−21−21−23−26−18−49−20−19
Income tax expense000000000100
Net income from continuing operations−18−25−20−22−21−21−23−26−18−50−20−19
Net income−18−25−20−22−21−21−23−26−18−50−20−19
EPS, basic−$2.03−$4.89−$2.44−$2.43−$2.26−$2.26−$2.49−$2.74−$1.92−$5.33−$1.69−$1.07
EPS, diluted−$2.03−$4.89−$2.44−$2.43−$2.26−$2.26−$2.49−$2.74−$1.92−$5.33−$1.69−$1.07
Weighted average shares, basic68899999991218
Weighted average shares, diluted68899999991218
EBITDA−18−26−21−23−22−22−24−26−17−15−20−20
Depreciation & amortization111111111100
EBIT−19−27−21−24−23−23−25−27−18−16−20−20